epocrates logo
epocrates logo
epocrates logo
  • 0

Herbs & Supplements

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Formulary
No Formulary Selected

close

 

Select a medication above to begin.

genistein (soy)

soy (Glycine max)

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • Alzheimer dementia [Insufficient Evidence]
  • asthma [Insufficient Evidence]
  • BPH [Possibly Ineffective]
  • cancer prevention, breast [Possibly Effective]
  • cancer prevention, cervical [Insufficient Evidence]
  • cancer prevention, colorectal [Possibly Ineffective]
  • cancer prevention, endometrial [Insufficient Evidence]
  • cancer prevention, gastric [Insufficient Evidence]
  • cancer prevention, lung [Insufficient Evidence]
  • cancer prevention, thyroid [Insufficient Evidence]
  • cardiovascular disease prevention [Insufficient Evidence]
  • child growth [Insufficient Evidence]
  • CKD [Possibly Effective]
  • cognitive function [Insufficient Evidence]
  • cognitive impairment [Insufficient Evidence]
  • colic [Insufficient Evidence]
  • Crohn disease [Insufficient Evidence]
  • diabetes mellitus [Possibly Effective]
  • diabetic nephropathy [Insufficient Evidence]
  • diarrhea [Possibly Effective]
  • dyspepsia [Insufficient Evidence]
  • exercise-induced muscle soreness [Possibly Ineffective]
  • fibromyalgia [Insufficient Evidence]
  • galactosemia [Possibly Effective]
  • hepatitis C [Insufficient Evidence]
  • hot flashes, androgen deprivation tx-associated [Insufficient Evidence]
  • hot flashes, breast CA-associated [Possibly Ineffective]
  • HTN [Possibly Effective]
  • hyperlipidemia [Possibly Effective]
  • IBS [Insufficient Evidence]
  • lactose intolerance [Possibly Effective]
  • mastalgia [Insufficient Evidence]
  • menopausal symptoms [Possibly Effective]
  • menstrual migraine prophylaxis [Insufficient Evidence]
  • metabolic syndrome [Possibly Effective]
  • muscle strength [Possibly Effective]
  • neonatal jaundice prevention [Insufficient Evidence]
  • metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
  • obesity [Insufficient Evidence]
  • osteoarthritis [Insufficient Evidence]
  • osteoporosis [Possibly Effective]
  • overall mortality [Insufficient Evidence]
  • polycystic ovary syndrome [Insufficient Evidence]
  • postmenopausal conditions [Insufficient Evidence]
  • premenstrual syndrome [Insufficient Evidence]
  • preterm labor prevention [Insufficient Evidence]
  • prostate CA [Insufficient Evidence]
  • rheumatoid arthritis [Insufficient Evidence]
  • sarcopenia [Insufficient Evidence]
  • stroke [Insufficient Evidence]
  • vaginal atrophy [Insufficient Evidence]
  • wrinkled skin [Insufficient Evidence]

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information